NeRRE Therapeutics picks up Series B funds
UK-based NeRRe Therapeutics, a developer of neurokinin receptor antagonists that treat conditions caused by neuronal hypersensitivity, has secured 23 million pounds in Series B funding. The investors were Fountain Healthcare Partners, Forbion Capital Partners, OrbiMed, Advent Life Sciences and Novo A/S.
5 January 2017•1 min read
